Kodiak(KOD) - 2025 Q2 - Quarterly Results

Exhibit 99.1 • Tarcocimab – Phase 3 topline data expected in 1Q 2026 (6 months) and 3Q 2026 (12 months) o Phase 3 GLOW2 diabetic retinopathy study – topline data on track for 1Q 2026 o Phase 3 DAYBREAK wet AMD study – topline data expected 3Q 2026 o Completed the manufacturing and release of BLA-facing commercial-scale batches in Kodiak's URSUS facility • KSI-501 – Phase 3 topline data expected in 3Q 2026 (12 months) o Phase 3 DAYBREAK wet AMD study – topline data expected 3Q 2026 o Planning for second Phas ...